Healthpeak Properties (DOC) to Post Quarterly Earnings on Tuesday

Healthpeak Properties (NYSE:DOC) is anticipated to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of $0.0282 per share and revenue of $725.6440 million for the quarter. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Healthpeak Properties (NYSE:DOC) last issued its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $752.95 million during the quarter, compared to the consensus estimate of $694.59 million. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The company’s revenue was up 7.1% on a year-over-year basis. During the same period last year, the company earned $0.46 earnings per share. On average, analysts expect Healthpeak Properties to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Healthpeak Properties Price Performance

DOC opened at $21.83 on Friday. The firm has a market cap of $15.05 billion, a PE ratio of 68.21, a P/E/G ratio of 3.39 and a beta of 1.02. The stock has a 50-day moving average price of $21.01 and a 200-day moving average price of $18.65. Healthpeak Properties has a 1 year low of $15.70 and a 1 year high of $22.95. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.96 and a quick ratio of 2.96.

Healthpeak Properties Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Friday, September 25th. Shareholders of record on Monday, September 14th will be paid a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a yield of 5.6%. The ex-dividend date is Monday, September 14th. Healthpeak Properties’s dividend payout ratio (DPR) is currently 381.25%.

Insider Activity

In other news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares in the company, valued at $148,520.20. The trade was a 59.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fiduciary Trust Co boosted its holdings in Healthpeak Properties by 4.9% in the third quarter. Fiduciary Trust Co now owns 13,807 shares of the real estate investment trust’s stock worth $264,000 after purchasing an additional 644 shares during the last quarter. Quadrant Capital Group LLC raised its stake in Healthpeak Properties by 1.9% during the 3rd quarter. Quadrant Capital Group LLC now owns 37,650 shares of the real estate investment trust’s stock valued at $721,000 after buying an additional 718 shares during the last quarter. Corient Private Wealth LLC raised its stake in Healthpeak Properties by 1.0% during the 2nd quarter. Corient Private Wealth LLC now owns 104,109 shares of the real estate investment trust’s stock valued at $1,823,000 after buying an additional 1,010 shares during the last quarter. Victory Financial Group LLC lifted its holdings in shares of Healthpeak Properties by 11.3% during the 3rd quarter. Victory Financial Group LLC now owns 11,189 shares of the real estate investment trust’s stock valued at $215,000 after buying an additional 1,139 shares during the period. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Healthpeak Properties by 7.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 18,084 shares of the real estate investment trust’s stock worth $366,000 after buying an additional 1,231 shares during the last quarter. Institutional investors own 93.57% of the company’s stock.

Analyst Ratings Changes

DOC has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $22.00 target price (up from $20.00) on shares of Healthpeak Properties in a report on Thursday, June 11th. Citigroup increased their price target on shares of Healthpeak Properties from $17.50 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Royal Bank Of Canada raised their price target on shares of Healthpeak Properties from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. BMO Capital Markets boosted their price objective on shares of Healthpeak Properties from $20.00 to $24.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, Robert W. Baird upped their price objective on Healthpeak Properties from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.62.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.